Article Text

Download PDFPDF

How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis
  1. A Choudhury,
  2. G Y H Lip
  1. Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
  1. Correspondence to:
    Professor Gregory Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK; g.y.h.lipbham.ac.uk

Abstract

There continues to be a wide variation of opinion among UK consultants regarding the best treatment strategies for ensuring effective thromboprophylaxis of atrial fibrillation

  • anticoagulation
  • atrial fibrillation
  • thromboprophylaxis
View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: GYHL is Clinical Adviser to the Guideline Development Group developing the NICE Guidelines on Atrial Fibrillation. In addition, he has received research funding and honoraria for meetings, educational symposia and advisory boards from various pharmaceutical companies involved in antithrombotic agents and other drugs used in the management of atrial fibrillation.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.